Kisselev AF - Search Results

1

Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2.

Ibtisam I, Kisselev AF. Ibtisam I, et al. Among authors: kisselev af. bioRxiv [Preprint]. 2023 Nov 28:2023.08.03.550647. doi: 10.1101/2023.08.03.550647. bioRxiv. 2023. Update in: Elife. 2024 Apr 15;12:RP91678. doi: 10.7554/eLife.91678 PMID: 37577495 Free PMC article. Updated. Preprint.

2

Site-Specific Proteasome Inhibitors.

Kisselev AF. Kisselev AF. Biomolecules. 2021 Dec 31;12(1):54. doi: 10.3390/biom12010054. Biomolecules. 2021. PMID: 35053202 Free PMC article. Review.

3

Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2.

Ibtisam I, Kisselev AF. Ibtisam I, et al. Among authors: kisselev af. Elife. 2024 Apr 15;12:RP91678. doi: 10.7554/eLife.91678. Elife. 2024. PMID: 38619391 Free PMC article.

4

A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.

Downey-Kopyscinski SL, Srinivasa S, Kisselev AF. Downey-Kopyscinski SL, et al. Among authors: kisselev af. Sci Rep. 2022 Jul 27;12(1):12788. doi: 10.1038/s41598-022-17239-3. Sci Rep. 2022. PMID: 35896610 Free PMC article.

5

Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.

Maurits E, Degeling CG, Kisselev AF, Florea BI, Overkleeft HS. Maurits E, et al. Among authors: kisselev af. Chembiochem. 2020 Nov 16;21(22):3220-3224. doi: 10.1002/cbic.202000375. Epub 2020 Jul 29. Chembiochem. 2020. PMID: 32598532 Free PMC article.

6

DNA-Histone Cross-Links: Formation and Repair.

Pachva MC, Kisselev AF, Matkarimov BT, Saparbaev M, Groisman R. Pachva MC, et al. Among authors: kisselev af. Front Cell Dev Biol. 2020 Dec 21;8:607045. doi: 10.3389/fcell.2020.607045. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33409281 Free PMC article. Review.

7

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.

Jenkins TW, Downey-Kopyscinski SL, Fields JL, Rahme GJ, Colley WC, Israel MA, Maksimenko AV, Fiering SN, Kisselev AF. Jenkins TW, et al. Among authors: kisselev af. Sci Rep. 2021 May 25;11(1):10883. doi: 10.1038/s41598-021-90451-9. Sci Rep. 2021. PMID: 34035431 Free PMC article.

8

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.

Schwartz G, Shee K, Romo B, Marotti J, Kisselev A, Lewis L, Miller T. Schwartz G, et al. Oncologist. 2021 Jun;26(6):467-e924. doi: 10.1002/onco.13733. Epub 2021 Mar 18. Oncologist. 2021. PMID: 33641211 Free PMC article. Clinical Trial.

9

Joining the army of proteasome inhibitors.

Kisselev AF. Kisselev AF. Chem Biol. 2008 May;15(5):419-21. doi: 10.1016/j.chembiol.2008.04.010. Chem Biol. 2008. PMID: 18482693

10

Use of proteasome inhibitors.

Downey SL, Florea BI, Overkleeft HS, Kisselev AF. Downey SL, et al. Among authors: kisselev af. Curr Protoc Immunol. 2015 Apr 1;109:9.10.1-9.10.8. doi: 10.1002/0471142735.im0910s109. Curr Protoc Immunol. 2015. PMID: 25845565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters